-+ 0.00%
-+ 0.00%
-+ 0.00%

IceCure expects Q1 US ProSense revenue to rise over 30% on year

PUBT·04/21/2026 12:34:04
Listen to the news
IceCure expects Q1 US ProSense revenue to rise over 30% on year
  • IceCure projected Q1 2026 U.S. revenue from ProSense systems and cryoprobes rose more than 30% versus Q1 2025, based on preliminary unaudited estimates.
  • Commercial uplift followed FDA clearance in October 2025 for ProSense use in local treatment of low-risk breast cancer in women aged 70 and older.
  • Management expects to close additional U.S. ProSense system sales in Q2 2026 as it expands installed base at academic and research hospitals.
  • IceCure scheduled release of full Q1 2026 operating and financial results for May 14, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN38236) on April 21, 2026, and is solely responsible for the information contained therein.